PDF(Pubmed)
Abstract：
Psoriasis is a chronic disease involving the skin, which significantly impacts the quality of life. Disease severity and treatment efficacy (i.e., response) are assessed through the Psoriasis Area and Severity Index (PASI). A PASI 75 response, i.e., an improvement of at least 75% with respect to the baseline PASI score, has traditionally been used as a therapeutic benchmark in clinical trials. Therapeutic advances have made PASI 90 or PASI 100 responses possible in most patients treated with some biologics. A greater response may generate social value beyond clinical outcomes that would benefit both patients and society.
A 1-year economic model was applied to estimate the impact of having a PASI 75, PASI 90, or PASI 100 response in four areas of analysis (quality of life, activities of daily living, work productivity, and out-of-pocket expenditures) and the social value of having a PASI 90 or PASI 100 response in comparison with a PASI 75 response. A mixed-methods approach based on the scientific literature, a focus group with patient, and an advisory committee with psoriasis stakeholders was used. The model included three different scenarios: having a PASI 90 vs a PASI 75 response; a PASI 100 vs a PASI 90 response; and a PASI 100 vs a PASI 75 response. A sensitivity analysis was included.
The annual economic impact per patient with moderate-to-severe plaque psoriasis having a PASI 75 response was estimated at Ł 6,139, mainly related to labour productivity losses and quality of life reductions. Having a PASI 90 or a PASI 100 response would reduce this impact to €3,956 or €1,353, respectively. Accordingly, the social value of having a PASI 90 instead of a PASI 75 response was estimated at €2,183, and €4,786 with a PASI 100 response.
A PASI 90 or PASI 100 response would have a lower economic impact and a greater social value than a PASI 75 response for patients with moderate-to-severe plaque psoriasis.
A 1-year economic model was applied to estimate the impact of having a PASI 75, PASI 90, or PASI 100 response in four areas of analysis (quality of life, activities of daily living, work productivity, and out-of-pocket expenditures) and the social value of having a PASI 90 or PASI 100 response in comparison with a PASI 75 response. A mixed-methods approach based on the scientific literature, a focus group with patient, and an advisory committee with psoriasis stakeholders was used. The model included three different scenarios: having a PASI 90 vs a PASI 75 response; a PASI 100 vs a PASI 90 response; and a PASI 100 vs a PASI 75 response. A sensitivity analysis was included.
The annual economic impact per patient with moderate-to-severe plaque psoriasis having a PASI 75 response was estimated at Ł 6,139, mainly related to labour productivity losses and quality of life reductions. Having a PASI 90 or a PASI 100 response would reduce this impact to €3,956 or €1,353, respectively. Accordingly, the social value of having a PASI 90 instead of a PASI 75 response was estimated at €2,183, and €4,786 with a PASI 100 response.
A PASI 90 or PASI 100 response would have a lower economic impact and a greater social value than a PASI 75 response for patients with moderate-to-severe plaque psoriasis.
摘要：
未经证实：银屑病是一种涉及皮肤的慢性疾病，这显著影响了生活质量。疾病严重程度和治疗效果(即，反应）通过牛皮癣面积和严重程度指数（PASI）进行评估。PASI75的回应，即，相对于基线PASI评分至少75％的改善，传统上被用作临床试验中的治疗基准。治疗进展使PASI90或PASI100应答在大多数用一些生物制剂治疗的患者中成为可能。更大的反应可能会产生超出临床结果的社会价值，从而使患者和社会受益。
UNASSIGNED：在四个分析领域（生活质量，日常生活活动,工作效率，和自付支出）以及与PASI75响应相比，PASI90或PASI100响应的社会价值。基于科学文献的混合方法方法，一个有病人的焦点小组，并使用了一个与银屑病相关的咨询委员会.该模型包括三种不同的情况：PASI90对PASI75响应；PASI100对PASI90响应；以及PASI100对PASI75响应。包括敏感性分析。
UNASSIGNED：估计每位具有PASI75反应的中度至重度斑块状银屑病患者的年度经济影响为6,139，主要与劳动生产率损失和生活质量下降有关。对PASI90或PASI100做出回应将使这一影响分别减少到3,956欧元或1,353欧元。因此，PASI90而不是PASI75响应的社会价值估计为2,183欧元，PASI100响应为4,786欧元。
未经评估：对于中度至重度斑块型银屑病患者，PASI90或PASI100应答比PASI75应答具有更低的经济影响和更高的社会价值。
UNASSIGNED：在四个分析领域（生活质量，
UNASSIGNED：估计每位具有PASI75反应的中度至重度斑块状银屑病患者的年度经济影响为6,139，主要与劳动生产率损失和生活质量下降有关。
未经评估：对于中度至重度斑块型银屑病患者，PASI90或PASI100应答比PASI75应答具有更低的经济影响和更高的社会价值。
